Heuck相关文献与解析，生知库 | 链接生命科学的每一步

Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study

Talquetamab（一种GPRC5D×CD3双特异性抗体）治疗中国复发/难治性多发性骨髓瘤患者的疗效和安全性：来自MonumentTAL-1 1/2期研究

doi:10.3324/haematol.2025.287334

An, Gang; Jin, Jie; Cai, Zhen; Jing, Hongmei; Fu, Chengcheng; He, Pengcheng; Xia, Zhongjun; Liu, Rui; Li, Liang; Gai, Xue; Zhang, Hong; Zhu, Dian; Luo, Xinchao; Sun, Binbin; Xu, Hongmei; Zhou, Longen; Campagna, Michela; Masterson, Tara J; Lau, Bonnie W; Renaud, Thomas; Heuck, Christoph; Singh, Indrajeet; Vishwamitra, Deeksha; Qiu, Lugui

Fortification of FeS Clusters Reshapes Anaerobic CO Dehydrogenase into an Air-Viable Enzyme Through Multilayered Sealing of O(2) Tunnels

FeS簇的强化通过多层密封O(2)通道，将厌氧CO脱氢酶重塑为一种可在空气中发挥作用的酶。

期刊:Angewandte Chemie-International Edition

影响因子:16.9

doi:10.1002/anie.202508565

Kim, Suk Min; Kong, So Yeon; Kang, Jingu; Ji, Jeong Seok; Kang, Sung Heuck; Yoon, Hye-Jin; Kim, Hyunwoo; Ryu, Jungki; Lee, Hyung Ho; Kim, Yong Hwan

发表日期：2025

文献求助收藏

Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology Results

MonumentTAL-1研究中推荐的Talquetamab治疗复发/难治性多发性骨髓瘤患者的II期剂量：临床药理学结果

期刊:Clinical Pharmacology & Therapeutics

影响因子:5.5

doi:10.1002/cpt.70004

Gong, Jue; Zhou, Jie; Yuan, Dongfen; Ma, Xuewen; Vishwamitra, Deeksha; Hilder, Brandi; Masterson, Tara J; Tolbert, Jaszianne; Renaud, Thomas; Heuck, Christoph; Kane, Colleen; Samtani, Mahesh N; Girgis, Suzette; Haddish-Berhane, Nahor; Berdeja, Jesus; Krishnan, Amrita; Ouellet, Daniele

Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 study

塔奎他单抗可改善复发或难治性多发性骨髓瘤患者的自述症状和健康相关生活质量：来自 1/2 期 MonumentTAL-1 研究的结果

期刊:Cancer

影响因子:5.1

doi:10.1002/cncr.35927

Schinke, Carolina; Touzeau, Cyrille; Oriol, Albert; Mateos, María-Victoria; Stevens, Don; Rasche, Leo; Qin, Xiang; Kato, Kelly; Bathija, Sacheeta; Katz, Eva G; Gries, Katharine S; Campagna, Michela; Masterson, Tara; Hilder, Brandi W; Tolbert, Jaszianne; Renaud, Thomas; Heuck, Christoph; Tomlinson, Chalmer; Moreau, Philippe; San-Miguel, Jesús; Rodríguez-Otero, Paula; Chari, Ajai

Trigonelline activates NRF2 and awakens dormant ovarian follicles to promote pregnancy in aging mice.

葫芦巴碱可激活 NRF2 并唤醒休眠的卵巢卵泡，从而促进老年小鼠怀孕。

期刊:iScience

影响因子:4.1

doi:10.1016/j.isci.2025.113717

Amoushahi Mahboobeh, Ernst Emil Hagen, Heuck Anders, Dueholm Margit, Ernst Erik, Lykke-Hartmann Karin

NRF2

发表日期：2025

文献求助收藏

Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma

多发性骨髓瘤进展过程中肿瘤及肿瘤微环境的免疫表型变化

期刊:PLoS Genetics

影响因子:3.7

doi:10.1371/journal.pgen.1011848

Bergiers, Isabelle; Köse, Murat Cem; Skerget, Sheri; Malfait, Milan; Fourneau, Nele; Ellis, Jenna-Claire; Vanhoof, Greet; Smets, Tina; Verbist, Bie; De Maeyer, Dries; Van Houdt, Jeroen; Van der Borght, Koen; Verona, Raluca; Heidrich, Bradley; Kurth, William; Delforge, Michel; Meuleman, Nathalie; Van Droogenbroeck, Jan; Vlummens, Philip; Heuck, Christoph J; Beguin, Yves; Bahlis, Nizar; Casneuf, Tineke; Caers, Jo

Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma

复发/难治性多发性骨髓瘤患者接受Talquetamab治疗的MonumentTAL-1研究中细胞因子释放综合征的特征分析和管理

期刊:Cancer Medicine

影响因子:3.1

doi:10.1002/cam4.71276

van de Donk, Niels W C J; Chari, Ajai; Martin, Thomas; Krishnan, Amrita; Rasche, Leo; Ye, Jing Christine; Popat, Rakesh; Lipe, Brea; Rodriguez, Cesar; Schinke, Carolina; Skerget, Sheri; Vishwamitra, Deeksha; Verona, Raluca; Gong, Jue; Singh, Indrajeet; Campagna, Michela; Masterson, Tara; Hilder, Brandi; Tolbert, Jaszianne; Renaud, Thomas; Smit, M Damiette; Heuck, Christoph; Mateos, Maria-Victoria

Outcomes in patients with relapsed/refractory multiple myeloma with extramedullary disease: a meta-analysis

复发/难治性多发性骨髓瘤伴髓外病变患者的预后：一项荟萃分析

期刊:Annals of Hematology

影响因子:2.4

doi:10.1007/s00277-025-06705-3

Voorhees, Peter M; Kumar, Shaji; Usmani, Saad Z; Ye, Jing Christine; Cohen, Yael C; Scott, Emma; Carson, Robin L; Heuck, Christoph; Gan, Ryan; Ackerman, Benjamin; Zhang, Jenny; Caplan, Eleanor; Parekh, Trilok; Mateos, María-Victoria

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

证据荟萃分析：评估微小残留病灶作为多发性骨髓瘤的中间临床终点

期刊:Blood

影响因子:23.1

doi:10.1182/blood.2024024371

Landgren, Ola; Prior, Thomas J; Masterson, Tara; Heuck, Christoph; Bueno, Orlando F; Dash, Ajeeta B; Einsele, Hermann; Goldschmidt, Hartmut; Knop, Stefan; Li, Cong; Mellqvist, Ulf-Henrik; McFadden, Ian; Oprea, Corina; Ross, Jeremy A; Talpes, Mihaela; Hydren, Jay R; Ahlstrom, Jennifer M; Kazandjian, Dickran; Weinhold, Niels; Zhang, Rick; Stetler-Stevenson, Maryalice; Marti, Gerald; Devlin, Sean M

Nanoelectromechanical Spectral Control of Silicon Bowtie Nanocavities for Quantum Light Sources

用于量子光源的硅蝶形纳米腔的纳米机电光谱控制

Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study

Talquetamab（一种GPRC5D×CD3双特异性抗体）治疗中国复发/难治性多发性骨髓瘤患者的疗效和安全性：来自MonumentTAL-1 1/2期研究

Fortification of FeS Clusters Reshapes Anaerobic CO Dehydrogenase into an Air-Viable Enzyme Through Multilayered Sealing of O(2) Tunnels

FeS簇的强化通过多层密封O(2)通道，将厌氧CO脱氢酶重塑为一种可在空气中发挥作用的酶。

Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology Results

MonumentTAL-1研究中推荐的Talquetamab治疗复发/难治性多发性骨髓瘤患者的II期剂量：临床药理学结果

Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 study

塔奎他单抗可改善复发或难治性多发性骨髓瘤患者的自述症状和健康相关生活质量：来自 1/2 期 MonumentTAL-1 研究的结果

Trigonelline activates NRF2 and awakens dormant ovarian follicles to promote pregnancy in aging mice.

葫芦巴碱可激活 NRF2 并唤醒休眠的卵巢卵泡，从而促进老年小鼠怀孕。

Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma

多发性骨髓瘤进展过程中肿瘤及肿瘤微环境的免疫表型变化

Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma

复发/难治性多发性骨髓瘤患者接受Talquetamab治疗的MonumentTAL-1研究中细胞因子释放综合征的特征分析和管理

Outcomes in patients with relapsed/refractory multiple myeloma with extramedullary disease: a meta-analysis

复发/难治性多发性骨髓瘤伴髓外病变患者的预后：一项荟萃分析

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

证据荟萃分析：评估微小残留病灶作为多发性骨髓瘤的中间临床终点